Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opioid analgesics

Big increase in opioid prescriptions and related hospital admissions since 2000

Looking at primary care data, researchers have found that opioids were over twice as likely to be prescribed as benzodiazepines or GABAergic medicines.

opioids us medicine bottles ss 17

Source: Shutterstock.com

Researchers have analysed primary care prescribing data and found that in 2015, opioids were twice as likely to be prescribed as benzodiazepines, Z-drugs or GABAergic medicines

The proportion of patients prescribed opioids and Z-drugs doubled between 2000 and 2012, according to the results of a study into prescribing patterns in dependence-forming medicines, by the Public Health Research Consortium (PHRC)[1].

Looking at primary care prescribing data from the Clinical Practice Research Datalink, the researchers found that in 2015, opioids were over twice as likely to be prescribed as benzodiazepines, Z-drugs, or GABAergic medicines. Opioids were issued to 1 patient in 20 whereas benzodiazepines, Z-drugs and GABAergic medicines were each prescribed to around 1 patient in 50.

As well as the numbers of prescriptions, there has also been an upward trend in the length of continuous prescribing periods, especially for opioids which increased from 64 days in 2000, to a peak of 102 days in 2013 and 2014.

Neil Smith, research director at the National Centre for Social Research who conducted the study on behalf of the PHRC, said the report highlights the fact that a balance needs to be struck between ensuring proper access to medicines to relieve suffering and avoiding prescribing that might cause harm such as dependence.

“Clinical guidance recommending more cautious and time limited prescribing of benzodiazepines may well have been effective in changing practice, with reductions in the extent and length of benzodiazepine prescribing,” he said.

“Trends in the extent and duration of opioid prescribing however, needs ongoing monitoring.”

Roger Knaggs, a pharmacist specialising in anaesthesia and pain management said that if analgesic medicines were likely to be of benefit for a patient, some improvement in pain and function would usually be apparent within a few weeks.

“If there is no benefit within a couple of months, it is unlikely to be effective and the dose should be tapered and not increased,” he explained.

“Over recent years, opioid medicines have been prescribed more commonly for other types of long-term pain such as back pain, arthritis or nerve pain. However, there is no evidence that they are effective in the longer term (over one year) for these types of pain.”

In addition to this report, data from NHS Digital, published on 31 August 2017, showed that in England the number of patients admitted to hospital for overdosing on opioid painkillers almost doubled in the last decade, from 4,312 in 2005–2006 to 8,219 in 2016. Poisoning from other synthetic narcotics also increased more than four-fold from 579 in 2005–2006 to 2,780 in 2016–2017.

Knaggs said that there were probably many reasons for this finding.

“This is most likely to be associated with a large increase in prescribing since 2005 (more than 100%) and people may have been obtaining these medicines from sources other than their GP, such as family or friends, illicit sources or over the internet,” he said.

“Also, more patients are being discharged earlier after surgery with supplies of opioids, and prescription is continued in the community without regular review.”

He added that managing pain was complex and medicines formed just a small part of the overall treatment plan for a patient.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203590

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • BNF for Children (BNFC) 2019-2020

    BNF for Children (BNFC) 2019-2020

    The BNFC contains essential practical information for all healthcare professionals involved in prescribing, dispensing, monitoring and administration of medicines to children.

    £59.95Buy now
  • Good Pharmacovigilance Practice Guide

    Good Pharmacovigilance Practice Guide

    An essential guide on pharmacovigilance of medicinal products for human use. Practical advice for developing effective pharmacovigilance systems.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • opioids us medicine bottles ss 17

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.